Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF U.S. HUMAN MICROBIOME MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL
4.2 PORTER'S FIVE FORCES MODEL
4.3 GLOBAL HUMAN MICROBIOME MARKET ANALYSIS
4.4 GUT MICROBIOME AND DIAGNOSTIC
5 EPIDEMIOLOGY
5.1 EPIDEMIOLOGY CANCER
5.2 EPIDEMIOLOGY DERMATOLOGICAL DISORDERS
5.3 EPIDEMIOLOGY GASTRIC DISORDERS
5.4 EPIDEMIOLOGY IMMUNE DISORDERS
5.5 EPIDEMIOLOGY METABOLIC DISORDERS
6 INDUSTRY INSIGHTS
6.1 DEMOGRAPHIC TRENDS
6.2 KEY PRICING STRATEGIES
7 INDUSTRY INSIGHT
7.1 PATENT ANALYSIS
7.2 PATENT FLOW DIAGRAM
8 REGULATORY FRAMEWORKS
8.1 UNITED STATES
8.2 EUROPE
9 MARKET OVERVIEW
9.1 DRIVERS
9.1.1 RISING PREVALENCE OF LIFESTYLE AND CHRONIC DISEASES
9.1.2 HUMAN MICROBIOME THERAPEUTIC DEVELOPMENT FOR DISEASE TREATMENT
9.1.3 INCREASING TECHNOLOGICAL ADVANCEMENTS IN METAGENOMICS AND NEXT-GENERATION SEQUENCING
9.2 RESTRAINTS
9.2.1 BARRIERS PROVING THE CAUSAL LINK BETWEEN DYSBIOSIS AND DISEASES
9.2.2 LACK OF TECHNOLOGY EXPERTISE
9.3 OPPORTUNITIES
9.3.1 RISE IN HEALTHCARE EXPENDITURE
9.3.2 INCREASING RESEARCH AND DEVELOPMENT
9.4 CHALLENGE
9.4.1 RISK ASSOCIATED WITH HUMAN MICROBIOME PRODUCTS
10 U.S. HUMAN MICROBIOME MARKET, BY PRODUCT
10.1 OVERVIEW
10.2 PROBIOTICS
10.2.1 BRANDED
10.2.1.1 OPTIPAC-PREBIOTICS FIBRE
10.2.1.2 ENZYMEDICA-PREBIOTICS DRINK MIX
10.2.1.3 SWEETBIOTIX
10.2.1.4 OTHERS
10.2.2 GENERICS
10.3 PREBIOTICS
10.3.1 BRANDED
10.3.1.1 BIOM PROBIOTIC
10.3.1.2 BIOM D FEND
10.3.1.3 FLORE GUT MICROBIOME TEST
10.3.1.4 REVITIFY
10.3.1.5 SYMBIOTIC YOGURT
10.3.1.6 SYMBIOTIC
10.3.1.7 LPLDL
10.3.1.8 LPGOS
10.3.1.9 OTHERS
10.3.2 GENERICS
10.4 SUPPLEMENTS
10.4.1 CHOLBIOME
10.4.2 LPGOS
10.4.3 WELL BIOME
10.4.4 FLORE BOOM
10.4.5 FLORE DEFENCE
10.4.6 FLORE BALANCE
10.4.7 BIOM
10.4.8 REVITIFY
10.4.9 FLORE
10.4.10 BIOM D FEND
10.4.11 SLIM BIOME
10.4.12 OTHERS
10.5 DIAGNOSTICS TESTS
10.5.1 FLORE GUT MICROBIOME TEST
10.5.2 FLORE 360
10.5.3 BIOME MICROBIOME TEST
10.5.4 SUPER GUT MICROBIOME HEALTH TEST
10.5.5 HEALTH INTELLIGENCE TEST
10.5.6 GUT INTELLIGENCE TEST
10.5.7 X MARKER
10.5.8 ATLAS MICROBIOME TEST
10.5.9 1TEST 1
10.5.10 LIFE KIT
10.5.11 FOR A
10.5.12 OTHERS
10.6 DRUGS
10.6.1 OXABACT
10.6.2 SINTAX
10.6.3 SYNBIOTIC YOGURT
10.6.4 SYNBIOTIC 7
10.6.5 MICRORX
10.6.6 SLIM BIOME
10.6.7 SLIM BIOME MEDICAL
10.6.8 LPLDL
10.6.9 CHOLBIOME
10.6.10 OTHERS
10.7 FECAL MICROBIOTA TRANSPLANT
10.8 OTHERS
11 U.S. HUMAN MICROBIOME MARKET, BY APPLICATION
11.1 OVERVIEW
11.2 THERAPEUTIC
11.2.1 SINGLE STRAIN OR MULTI-STRAIN CONSORTIA
11.2.2 LIQUID OR DRIED BULK DRUG SUBSTANCE
11.2.3 SOLID ORAL DOSE
11.2.4 OTHERS
11.3 DIAGNOSTIC
11.3.1 IRRITABLE BOWEL SYNDROME
11.3.2 LEAKY GUT SYNDROME
11.3.3 DIABETES
11.3.4 BACTERIAL VAGINOSIS
11.3.5 GINGITIVIS
11.3.6 TRICHOMONIASIS
11.3.7 VAGINAL CANDIDIASIS
12 U.S. HUMAN MICROBIOME MARKET, BY DISEASE
12.1 OVERVIEW
12.2 INFECTIOUS DISEASE
12.2.1 HELICOBACTER PYLORI
12.2.2 C. DIFFICILE INFECTIONS
12.2.3 BACTERIAL VAGINOSIS
12.2.4 OTHERS
12.3 GASTROINTESTINAL DISORDERS
12.4 C. DIFFICILE INFECTION
12.5 METABOLIC DISORDER
12.5.1 DIABETES
12.5.2 OBESITY
12.5.3 ENDOCRINE
12.5.4 NON ALCOHOLIC LIVER DISEASE
12.6 AUTOIMMUNE DISORDER
12.7 CANCER
12.8 MENTAL DISORDER
12.9 DERMATOLOGICAL DISORDERS
12.9.1 ATOPIC DERMATITIS
12.9.2 ROSACEA
12.9.3 ACNE
12.9.4 OTHERS
12.1 PRIMARY HYPEROXYUREASOLUTION-PHASE
12.11 OTHERS
13 U.S. HUMAN MICROBIOME MARKET, BY TECHNOLOGY
13.1 OVERVIEW
13.2 GENOMICS
13.2.1 SEQUENCING
13.2.1.1 16S RRNA SEQUENCING METHOD
13.2.1.2 SHOTGUN METAGENOMICS SEQUENCING
13.2.1.3 WHOLE GENOME SEQUENCING
13.2.1.4 OTHER
13.2.2 POLYMERASE CHAIN REACTION
13.2.3 OTHER GENOMIC TECHNIQUES
13.2.4 ORGAN TRANSPLANTATION
13.2.5 OTHER CLINICAL APPLICATION
13.3 PROTEOMICS
13.3.1 EXPRESSION PROTEOMICS
13.3.2 FUNCTIONAL PROTEOMICS
13.3.3 STRUCTURAL PROTEOMICS
13.4 METABOLIMICS
13.4.1 TARGETED ANALYSIS
13.4.2 METABOLITE PROFILING
13.4.3 METABOLIC FINGERPRINTING
14 U.S. HUMAN MICROBIOME MARKET, BY TYPE
14.1 OVERVIEW
14.2 SMALL MOLECULE
14.3 BIOLOGIC
15 U.S. HUMAN MICROBIOME MARKET, BY END USER
15.1 OVERVIEW
15.2 ONLINE PHARMACIES
15.3 HYPERMARKET & SUPERMARKET
15.4 RETAIL PHARMACIES
15.5 HOSPITAL PHARMACIES
15.6 CLINICS
15.7 OTHERS
16 U.S. HUMAN MICROBIOME MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 RETAIL SALES
16.3 DIRECT TENDERS
17 U.S. HUMAN MICROBIOME MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: U.S.
18 COMPANY PROFILE
18.1 OPTIBIOTIX HEALTH PLC
18.1.1 COMPANY SNAPSHOT
18.1.2 PRODUCT PORTFOLIO
18.1.3 RECENT DEVELOPMENT
18.2 MERCK KGAA
18.2.1 COMPANY SNAPSHOT
18.2.2 PRODUCT PORTFOLIO
18.2.3 RECENT DEVELOPMENTS
18.3 FINCH THERAPEUTICS GROUP, INC
18.3.1 COMPANY SNAPSHOT
18.3.2 PIPELINE PRODUCT PORTFOLIO
18.3.3 RECENT DEVELOPMENT
18.4 FERRING B.V.
18.4.1 COMPANY SNAPSHOT
18.4.2 PIPELINE PRODUCT PORTFOLIO
18.4.3 RECENT DEVELOPMENTS
18.5 ATLAS BIOMED GROUP LIMITED
18.5.1 COMPANY SNAPSHOT
18.5.2 PRODUCT PORTFOLIO
18.5.3 RECENT DEVELOPMENTS
18.6 ENTEROME
18.6.1 COMPANY SNAPSHOT
18.6.2 PIPELINE PRODUCT PORTFOLIO
18.6.3 RECENT DEVELOPMENTS
18.7 ASSEMBLY BIOSCIENCES, INC.
18.7.1 COMPANY SNAPSHOT
18.7.2 PIPELINE PRODUCT PORTFOLIO
18.7.3 RECENT DEVELOPMENTS
18.8 BIOMX
18.8.1 COMPANY SNAPSHOT
18.8.2 PIPELINE PRODUCT PORTFOLIO
18.8.3 RECENT DEVELOPMENTS
18.9 EMBION TECHNOLOGIES S.A.
18.9.1 COMPANY SNAPSHOT
18.9.2 PIPELINE PRODUCT PORTFOLIO
18.9.3 RECENT DEVELOPMENTS
18.1 EVELO BIOSCIENCES, INC.
18.10.1 COMPANY SNAPSHOT
18.10.2 PIPELINE PRODUCT PORTFOLIO
18.10.3 RECENT DEVELOPMENTS
18.11 FLIGHTPATH BIOSCIENCES, INC.
18.11.1 COMPANY SNAPSHOT
18.11.2 PIPELINE PRODUCT PORTFOLIO
18.11.3 RECENT DEVELOPMENTS
18.12 GNUBIOTICS SCIENCES
18.12.1 COMPANY SNAPSHOT
18.12.2 PIPELINE PRODUCT PORTFOLIO
18.12.3 RECENT DEVELOPMENTS
18.13 IMMURON
18.13.1 COMPANY SNAPSHOT
18.13.2 PIPELINE PRODUCT PORTFOLIO
18.13.3 RECENT DEVELOPMENTS
18.14 LUXIA SCIENTIFIC
18.14.1 COMPANY SNAPSHOT
18.14.2 PRODUCT PORTFOLIO
18.14.3 RECENT DEVELOPMENTS
18.15 METABIOMICS
18.15.1 COMPANY SNAPSHOT
18.15.2 PRODUCT PORTFOLIO
18.15.3 RECENT DEVELOPMENTS
18.16 OSEL INC
18.16.1 COMPANY SNAPSHOT
18.16.2 PRODUCT PORTFOLIO
18.16.3 RECENT DEVELOPMENT
18.17 OXTHERA.
18.17.1 COMPANY SNAPSHOT
18.17.2 PIPELINE PRODUCT PORTFOLIO
18.17.3 RECENT DEVELOPMENTS
18.18 SECOND GENOME
18.18.1 COMPANY SNAPSHOT
18.18.2 PIPELINE PRODUCT PORTFOLIO
18.18.3 RECENT DEVELOPMENTS
18.19 SERES THERAPEUTICS
18.19.1 COMPANY SNAPSHOT
18.19.2 PIPELINE PRODUCT PORTFOLIO
18.19.3 RECENT DEVELOPMENTS
18.2 SUN GENOMICS
18.20.1 COMPANY SNAPSHOT
18.20.2 PRODUCT PORTFOLIO
18.20.3 RECENT DEVELOPMENTS
18.21 SYNTHETIC BIOLOGICS, INC..
18.21.1 COMPANY SNAPSHOT
18.21.2 PIPELINE PRODUCT PORTFOLIO
18.21.3 RECENT DEVELOPMENTS
18.22 SYNLOGIC
18.22.1 COMPANY SNAPSHOT
18.22.2 PIPELINE PRODUCT PORTFOLIO
18.22.3 RECENT DEVELOPMENTS
18.23 VEDANTA BIOSCIENCES, INC.
18.23.1 COMPANY SNAPSHOT
18.23.2 PIPELINE PRODUCT PORTFOLIO
18.23.3 RECENT DEVELOPMENTS
18.24 VIOME LIFESCIENCES, US
18.24.1 COMPANY SNAPSHOT
18.24.2 PRODUCT PORTFOLIO
18.24.3 RECENT DEVELOPMENT
18.25 YSOPIA BIOSCIENCE
18.25.1 COMPANY SNAPSHOT
18.25.2 PIPELINE PRODUCT PORTFOLIO
18.25.3 RECENT DEVELOPMENT
18.26 4D PHARMA PLC
18.26.1 COMPANY SNAPSHOT
18.26.2 PRODUCT PORTFOLIO
18.26.3 RECENT DEVELOPMENTS
19 QUESTIONNAIRE
20 RELATED REPORTS
List of Table
TABLE 1 PATENT ANALYSIS
TABLE 2 U.S. HUMAN MICROBIOME MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 3 U.S. PROBIOTICS IN HUMAN MICROBIOME MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 4 U.S. BRANDED IN HUMAN MICROBIOME MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 5 U.S. PREBIOTICS IN HUMAN MICROBIOME MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 6 U.S. BRANDED IN HUMAN MICROBIOME MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 7 U.S. SUPPLEMENTS IN HUMAN MICROBIOME MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 8 U.S. DIAGNOSTICS TESTS IN HUMAN MICROBIOME MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 9 U.S. DRUGS IN HUMAN MICROBIOME MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 10 U.S. HUMAN MICROBIOME MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 11 U.S. THERAPEUTIC IN HUMAN MICROBIOME MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 12 U.S. DIAGNOSTIC IN HUMAN MICROBIOME MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 13 U.S. HUMAN MICROBIOME MARKET, BY DISEASE, 2020-2029 (USD MILLION)
TABLE 14 U.S. INFECTIOUS DISEASE IN HUMAN MICROBIOME MARKET, BY DISEASE, 2020-2029 (USD MILLION)
TABLE 15 U.S. METABOLIC DISORDER IN HUMAN MICROBIOME MARKET, BY DISEASE, 2020-2029 (USD MILLION)
TABLE 16 U.S. DERMATOLOGICAL DISORDERS IN HUMAN MICROBIOME MARKET, BY DISEASE, 2020-2029 (USD MILLION)
TABLE 17 U.S. HUMAN MICROBIOME MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 18 U.S. GENOMICS IN HUMAN MICROBIOME MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 19 U.S. SEQUENCING IN HUMAN MICROBIOME MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 20 U.S. PROTEOMICS IN HUMAN MICROBIOME MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 21 U.S. METABOLOMICS IN HUMAN MICROBIOME MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 22 U.S. HUMAN MICROBIOME MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 23 U.S. HUMAN MICROBIOME MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 24 U.S. HUMAN MICROBIOME MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
List of Figure
FIGURE 1 U.S. HUMAN MICROBIOME MARKET: SEGMENTATION
FIGURE 2 U.S. HUMAN MICROBIOME MARKET: DATA TRIANGULATION
FIGURE 3 U.S. HUMAN MICROBIOME MARKET: DROC ANALYSIS
FIGURE 4 U.S. HUMAN MICROBIOME MARKET: U.S. VS REGIONAL MARKET ANALYSIS
FIGURE 5 U.S. HUMAN MICROBIOME MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 U.S. HUMAN MICROBIOME MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 U.S. HUMAN MICROBIOME MARKET: DBMR MARKET POSITION GRID
FIGURE 8 U.S. HUMAN MICROBIOME MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 U.S. HUMAN MICROBIOME MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 U.S. HUMAN MICROBIOME MARKET: SEGMENTATION
FIGURE 11 INCREASING TECHNOLOGICAL ADVANCEMENTS IN METAGENOMICS AND NEXT-GENERATION SEQUENCING ARE EXPECTED TO DRIVE THE U.S. HUMAN MICROBIOME MARKET GROWTH IN THE FORECAST PERIOD
FIGURE 12 PROBIOTICS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE U.S. HUMAN MICROBIOME MARKET IN 2022 & 2029
FIGURE 13 PATENT FLOW DIAGRAM FOR DRUGS IN THE U.S.
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF U.S. HUMAN MICROBIOME MARKET
FIGURE 15 U.S. HUMAN MICROBIOME MARKET: BY PRODUCT, 2021
FIGURE 16 U.S. HUMAN MICROBIOME MARKET: BY PRODUCT, 2022-2029 (USD MILLION)
FIGURE 17 U.S. HUMAN MICROBIOME MARKET: BY PRODUCT, CAGR (2022-2029)
FIGURE 18 U.S. HUMAN MICROBIOME MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 19 U.S. HUMAN MICROBIOME MARKET: BY APPLICATION, 2021
FIGURE 20 U.S. HUMAN MICROBIOME MARKET: BY APPLICATION, 2022-2029 (USD MILLION)
FIGURE 21 U.S. HUMAN MICROBIOME MARKET: BY APPLICATION, CAGR (2022-2029)
FIGURE 22 U.S. HUMAN MICROBIOME MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 23 U.S. HUMAN MICROBIOME MARKET: BY DISEASE, 2021
FIGURE 24 U.S. HUMAN MICROBIOME MARKET: BY DISEASE, 2022-2029 (USD MILLION)
FIGURE 25 U.S. HUMAN MICROBIOME MARKET: BY DISEASE, CAGR (2022-2029)
FIGURE 26 U.S. HUMAN MICROBIOME MARKET: BY DISEASE, LIFELINE CURVE
FIGURE 27 U.S. HUMAN MICROBIOME MARKET: BY TECHNOLOGY, 2021
FIGURE 28 U.S. HUMAN MICROBIOME MARKET: BY TECHNOLOGY, 2022-2029 (USD MILLION)
FIGURE 29 U.S. HUMAN MICROBIOME MARKET: BY TECHNOLOGY, CAGR (2022-2029)
FIGURE 30 U.S. HUMAN MICROBIOME MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 31 U.S. HUMAN MICROBIOME MARKET: BY TYPE, 2021
FIGURE 32 U.S. HUMAN MICROBIOME MARKET: BY TYPE, 2022-2029 (USD MILLION)
FIGURE 33 U.S. HUMAN MICROBIOME MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 34 U.S. HUMAN MICROBIOME MARKET: BY TYPE, LIFELINE CURVE
FIGURE 35 U.S. HUMAN MICROBIOME MARKET: BY END USER, 2021
FIGURE 36 U.S. HUMAN MICROBIOME MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 37 U.S. HUMAN MICROBIOME MARKET: BY END USER, CAGR (2022-2029)
FIGURE 38 U.S. HUMAN MICROBIOME MARKET: BY END USER, LIFELINE CURVE
FIGURE 39 U.S. HUMAN MICROBIOME MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 40 U.S. HUMAN MICROBIOME MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 41 U.S. HUMAN MICROBIOME MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 42 U.S. HUMAN MICROBIOME MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 43 U.S. HUMAN MICROBIOME MARKET: COMPANY SHARE 2021 (%)
